madman
Super Moderator
MP79-15 ERECTILE FUNCTION RECOVERY AMONG YOUNG MEN WITH ERECTILE DYSFUNCTION ON OAD TADALAFIL 5 MG: FINDINGS FROM A REAL-LIFE STUDY (2023)
Edoardo Pozzi*, Federico Belladelli, Giuseppe Fallara, Simone Cilio, Christian Corsini, Alessandro Bertini, Massimiliano Raffo, Fausto Negri, Ludovica Cella, Margherita Fantin, Francesco Lanzaro, Luigi Candela, Milan, Italy; Paolo Capogrosso, Varese, Italy; Luca Boeri, Alessia d'Arma, Francesco Montorsi, Andrea Salonia, Milan, Italy
INTRODUCTION AND OBJECTIVE
Daily tadalafil 5 mg provides a valuable alternative to on-demand tadalafil for men who prefer spontaneous to scheduled sexual attempts. We investigated the rate of and the clinical factors associated with erectile function (EF) recovery after discontinuation of 5 mg tadalafil OaD in a cohort of young men seeking medical help for ED as their primary complaint.
METHODS
Data from 96 consecutive young patients (<50 yr) with ED and prescribed 5 mg tadalafil OaD were analyzed. All patients were diagnosed with psychogenic ED after a comprehensive clinical evaluation including penile duplex ultrasound and hormonal profile assessment. All completed the International IIEF at baseline. The length of treatment varied from 1 to 12 months according to clinical judgment. EF recovery was assessed after 2 weeks from treatment discontinuation and defined as IIEF-EF >21 after daily 5 mg tadalafil discontinuation. Patients without EF recovery were classified as tadalafil OaD non-responders. Cox regression models tested the association between patients' baseline characteristics and the probability of EF recovery after treatment discontinuation. Kaplan-Meier analyses estimated the probability of EF recovery over time.
RESULTS
The Median (IQR) age was 39 (32-45) yr. Of all, 82 (85.4%) achieved EF recovery at treatment discontinuation, whilst 14 (14.6%) were identified as non-responders. The median treatment length was 3 (2-11) months. The most common treatment-related adverse effect was a headache in 9 (9.4%) patients. Non-responders were older (43 vs. 38, p[0.03), with higher BMI (25.54 vs. 23.6, p[0.04) and depicted lower IIEF-EF scores at baseline (12 vs. 15, p[0.02) than responders. No differences in terms of comorbidities (CC1), smoking, alcohol consumption, and regular physical exercise were detected. Kaplan Meier estimates of EF recovery at 3, 6, and 12 months, were 43% (95%CI: 41-62), 60% (95%CI: 49-69), and 75% (95%CI: 64-83), respectively (Figure 1). Younger age (HR: 0.95; 95% CI: 0.92-0.99, p[0.01) was associated with EF recovery after adjusting for baseline EF, BMI, smoking, and CCI1.
CONCLUSIONS
Almost one out of two young ED patients prescribed with tadalafil OaD achieved full EF recovery within 3 months of treatment. Younger patients have a higher probability of EF recovery with daily 5 mg tadalafil therapy.
Edoardo Pozzi*, Federico Belladelli, Giuseppe Fallara, Simone Cilio, Christian Corsini, Alessandro Bertini, Massimiliano Raffo, Fausto Negri, Ludovica Cella, Margherita Fantin, Francesco Lanzaro, Luigi Candela, Milan, Italy; Paolo Capogrosso, Varese, Italy; Luca Boeri, Alessia d'Arma, Francesco Montorsi, Andrea Salonia, Milan, Italy
INTRODUCTION AND OBJECTIVE
Daily tadalafil 5 mg provides a valuable alternative to on-demand tadalafil for men who prefer spontaneous to scheduled sexual attempts. We investigated the rate of and the clinical factors associated with erectile function (EF) recovery after discontinuation of 5 mg tadalafil OaD in a cohort of young men seeking medical help for ED as their primary complaint.
METHODS
Data from 96 consecutive young patients (<50 yr) with ED and prescribed 5 mg tadalafil OaD were analyzed. All patients were diagnosed with psychogenic ED after a comprehensive clinical evaluation including penile duplex ultrasound and hormonal profile assessment. All completed the International IIEF at baseline. The length of treatment varied from 1 to 12 months according to clinical judgment. EF recovery was assessed after 2 weeks from treatment discontinuation and defined as IIEF-EF >21 after daily 5 mg tadalafil discontinuation. Patients without EF recovery were classified as tadalafil OaD non-responders. Cox regression models tested the association between patients' baseline characteristics and the probability of EF recovery after treatment discontinuation. Kaplan-Meier analyses estimated the probability of EF recovery over time.
RESULTS
The Median (IQR) age was 39 (32-45) yr. Of all, 82 (85.4%) achieved EF recovery at treatment discontinuation, whilst 14 (14.6%) were identified as non-responders. The median treatment length was 3 (2-11) months. The most common treatment-related adverse effect was a headache in 9 (9.4%) patients. Non-responders were older (43 vs. 38, p[0.03), with higher BMI (25.54 vs. 23.6, p[0.04) and depicted lower IIEF-EF scores at baseline (12 vs. 15, p[0.02) than responders. No differences in terms of comorbidities (CC1), smoking, alcohol consumption, and regular physical exercise were detected. Kaplan Meier estimates of EF recovery at 3, 6, and 12 months, were 43% (95%CI: 41-62), 60% (95%CI: 49-69), and 75% (95%CI: 64-83), respectively (Figure 1). Younger age (HR: 0.95; 95% CI: 0.92-0.99, p[0.01) was associated with EF recovery after adjusting for baseline EF, BMI, smoking, and CCI1.
CONCLUSIONS
Almost one out of two young ED patients prescribed with tadalafil OaD achieved full EF recovery within 3 months of treatment. Younger patients have a higher probability of EF recovery with daily 5 mg tadalafil therapy.
